Adagene Inc at HC Wainwright Investment Conference - New York Transcript
All right, let's hit it. Good afternoon, everyone. My name is Arthur He, senior biotech analyst at H.C. Wainwright. Thanks for joining us to have a conversation with Dr. Peter Luo, the Chairman, CEO, and the Co-Founder of Adagene.
Adagene is a clinical-stage biopharmaceutical company focused on develop a novel antibody-based cancer therapy based on its proprietary platform, which including NEObody, POWERbody, and the SAFEbody. So the company currently has four clinical-stage assets and a number of preclinical programs. To discuss this program and the development strategy, I'd like to invite Peter to this conversation. Peter, thanks for coming down to talk to our audience.
Thanks, Arthur.
So just to help set the stage for our audience, could you give us an overview about the Adagene pipeline right now?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
